Clinical Trials Logo

Gastrointestinal Neoplasms clinical trials

View clinical trials related to Gastrointestinal Neoplasms.

Filter by:

NCT ID: NCT05318027 Recruiting - Lung Cancer Clinical Trials

ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy

Start date: May 22, 2023
Phase: N/A
Study type: Interventional

Evaluate the feasibility of using a chatbot combined with continuous activity monitoring to proactively identify, appropriately triage and help manage patients' symptoms during cancer treatment Determine whether such an early outpatient clinic-based intervention can decrease rates of excess triage visits Correlate changes in activity and early symptom management to emergency department visits, unplanned inpatient hospitalizations and treatment breaks

NCT ID: NCT05301556 Completed - Clinical trials for Gastrointestinal Cancer

Food for Special Medical Purpose in Patients With Digestive Tract Tumor

Start date: June 24, 2022
Phase: N/A
Study type: Interventional

This is a prospective, randomized, controlled, unblinded, parallel, multicenter, and non-inferiority study to demonstrate the safety and efficacy of a Food for Special Medical Purpose product (FSMP) in participants with digestive tract tumor undergoing surgical resection during the perioperative period.

NCT ID: NCT05287165 Recruiting - Clinical trials for Advanced Solid Tumors

Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms

Start date: March 10, 2022
Phase: Early Phase 1
Study type: Interventional

This is a open-label, single center to determine the efficacy and safety of IM96 CAR-T cells in Patients With Advanced Digestive System Neoplasms

NCT ID: NCT05280210 Not yet recruiting - Clinical trials for Gastrointestinal Neoplasms

PTC in Personalizing Neoadjuvant Therapy for Patients With Advanced Gastrointestinal Tumor

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

To explore the value of PTC drug screening technique in selecting neoadjuvant therapy for advanced gastrointestinal cancer.

NCT ID: NCT05277766 Recruiting - Colorectal Cancer Clinical Trials

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

PIPAC-NAL-IRI
Start date: November 21, 2022
Phase: Phase 1
Study type: Interventional

The PIPAC NAL-IRI study is designed to examine the maximal tolerated dose of nanoliposomal irinotecan (Nal-IRI, Onivyde) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a monocentric, phase I trial.

NCT ID: NCT05262491 Recruiting - Clinical trials for Gastrointestinal Tumor

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor

Start date: February 14, 2022
Phase: Phase 1
Study type: Interventional

In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic gastrointestinal tumor and other solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-B01D1. In phase Ib study, the safety and tolerability of BL-B01D1 at the phase Ia recommended dose will be further investigated, and recommended phase II dose (RP2D) for phase II clinical studies will be determined. In addition, the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-B01D1 in patients with locally advanced or metastatic gastrointestinal tumor and other solid tumor will be evaluated.

NCT ID: NCT05262335 Recruiting - Clinical trials for Gastrointestinal Tumors

Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)

ALTER-G-001
Start date: December 1, 2021
Phase: Phase 2
Study type: Interventional

This is an open, multi-cohort, multi-center, exploratory and phase II clinical trial. To evaluate the efficacy and safety Anlotinib combined with chemotherapy as first-line and maintenance therapy for Gastrointestinal Tumors with Unresectable Liver Metastases.

NCT ID: NCT05260385 Recruiting - Clinical trials for Digestive System Tumors

To Evaluate KC1036 in the Patients With Advanced Digestive System Tumors

Start date: January 24, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the preliminary efficacy, safety, tolerability and pharmacokinetics of KC1036 in participants with advanced recurrent or metastatic digestive system tumors.

NCT ID: NCT05252078 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients

ALTER-E005
Start date: June 2, 2022
Phase: Phase 2
Study type: Interventional

This is an Open, Single Arm, Exploratory and Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma (ESCC) Patients as Postoperative Adjuvant Therapy. In order to observe and evaluate the efficacy and safety of Anlotinib Hydrochloride Capsules combined with TQB2450 Injection in treatment of patients with ESCC. The primary endpoint is disease free survival (DFS).

NCT ID: NCT05238584 Recruiting - Gastric Cancer Clinical Trials

Total Versus Partial Omentectomy in the Treatment of Gastric Cancer

TOPO
Start date: January 1, 2022
Phase: N/A
Study type: Interventional

The main purpose of this study is to evaluate the role of the type of omentectomy (partial or total) in the treatment of Tis - T3 gastric cancer without serosal infiltration. The second purpose is to monitoring the blood levels of immunological factors (interleukins, T cell subtypes, etc.) pre-and postoperatively, depending on the type of omentectomy.